Editas Medicine

EDIT

Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado. It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church and patents from Partners Healthcare-MGH's J. Keith Joung. These four were co-founders and scientific advisory board members along with Jennifer Doudna.

Editas Medicine has been a target of short sellers for a while. The current short interest of 19.69% is significantly above the average of the last 12 months (9.18%).